Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$0.45.

  • Evoke Pharma's EPS (Basic) rose 5212.77% to -$0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.38, marking a year-over-year increase of 8755.64%. This contributed to the annual value of -$2.81 for FY2024, which is 8995.55% up from last year.
  • Per Evoke Pharma's latest filing, its EPS (Basic) stood at -$0.45 for Q3 2025, which was up 5212.77% from -$0.62 recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's EPS (Basic) registered a high of -$0.08 during Q1 2021, and its lowest value of -$7.13 during Q4 2023.
  • Its 5-year average for EPS (Basic) is -$1.67, with a median of -$0.71 in 2022.
  • As far as peak fluctuations go, Evoke Pharma's EPS (Basic) plummeted by 124528.3% in 2023, and later skyrocketed by 9121.88% in 2024.
  • Evoke Pharma's EPS (Basic) (Quarter) stood at -$0.61 in 2021, then grew by 13.11% to -$0.53 in 2022, then crashed by 1245.28% to -$7.13 in 2023, then soared by 91.22% to -$0.63 in 2024, then grew by 28.13% to -$0.45 in 2025.
  • Its EPS (Basic) stands at -$0.45 for Q3 2025, versus -$0.62 for Q2 2025 and -$0.51 for Q1 2025.